Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-GO1 phase 1/2 safety, PK, and PD study in healthy adults and patients with primary hyperoxaluria type 1
NL-OMON47017Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-blind trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoints: Incidence of adverse events and Safety assessments. Started Jan 2018; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NL-OMON47017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47017.